New Study From MD Anderson and BridgeBio's Navire Pharma Shows SHP2 Inhibition Overcomes Multiple Therapeutic-Resistance Mechanisms in Lung Cancer
September 15, 2020
September 15, 2020
HOUSTON, Texas, Sept. 15 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 14:
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that . . .
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that . . .